<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359979</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-20-7022-OS-CTIL</org_study_id>
    <nct_id>NCT04359979</nct_id>
  </id_info>
  <brief_title>Tamsulosin for Thyroid Lid Retraction</brief_title>
  <official_title>Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of using Tamsulosin for treatment of
      eyelid retraction as part of thyroid eye disease. The treatment will be offered to all
      thyroid patients suffering from eyelid retraction who are treated at the thyroid clinic in
      Sheba's Ophthalmology department. All patient will receive information about the drug
      Tamsulosin, the possible side effects, and the alternative treatment options for retraction.

      Patients recruited will take 0.4mg/day Tamsulosin for 3 months and will have follow-ups at 1
      week, 1 month and 3 months to evaluate the retraction status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid eye disease is a common autoimmune disorder caused by antibodies directed against
      receptors present in the thyroid cells and extra-ocular muscles and soft tissue of the orbit.
      The disorder is characterised by enlargement of the extra-ocular muscles, fatty and
      connective tissue volume.

      Upper lid retraction is the most common sign of the eye disease (present in up to 92%). The
      causes for retraction are not fully understood. It may be related to inflammation of the
      Levator muscle and the Muller muscle, or related to over sympathetic activity causing
      overstimulation of the Muller muscle.

      Upper lid retraction severity can range from very light to severe, with scleral show, eye
      dryness and even exposure keratopathy. Additionally it can have a very significant effect on
      the patient's appearance (a constant surprised look).

      Treatments for lid retraction include aggressive lubrication and tarsorrhaphy if needed
      (sewing the eyelids together).

      The Muller is a smooth muscle which elevates the upper eyelid and is sympathetically
      innervated (alpha receptor).

      The drug Tamsulosin which is a selective alpha1 receptor antagonist is commonly used today
      for benign prostatic hyperplasia (relaxing the prostate muscle).

      In this study we would like to test using Tamsulosin for treatment of lid retraction caused
      by thyroid eye disease. We hypothesise that the relaxation of the Muller muscle may have a
      beneficial effect on the retraction.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>off label use of an approved drug for new indication</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eyelid retraction</measure>
    <time_frame>1 week after starting tamsulosin treatment</time_frame>
    <description>measuring the upper margin to reflex distance (MRD1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eyelid retraction</measure>
    <time_frame>1 month after starting tamsulosin treatment</time_frame>
    <description>measuring the upper margin to reflex distance (MRD1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eyelid retraction</measure>
    <time_frame>3 months after starting tamsulosin treatment</time_frame>
    <description>measuring the upper margin to reflex distance (MRD1)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Thyroid Eye Disease</condition>
  <condition>Eyelid Diseases</condition>
  <arm_group>
    <arm_group_label>tamsulosin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive 0.4mg/day of Tamsulosin tablet for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>selective alpha1 receptor antagonist</description>
    <arm_group_label>tamsulosin treatment</arm_group_label>
    <other_name>Omnic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thyroid eye disease patients suffering from upper eyelid retraction in one or both
             eyes

        Exclusion Criteria:

          -  pregnant/breastfeeding women

          -  previous eyelid surgery/trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oded Sagiv, MD</last_name>
    <phone>972542007707</phone>
    <email>Oded.Sagiv@sheba.health.gov.il</email>
  </overall_contact>
  <reference>
    <citation>Yano S, Hirose M, Nakada T, Nakayama J, Matsuo K, Yamada M. Selective alpha 1A-adrenoceptor stimulation induces Mueller's smooth muscle contraction in an isolated canine upper eyelid preparation. Curr Eye Res. 2010 May;35(5):363-9. doi: 10.3109/02713680903518858.</citation>
    <PMID>20450248</PMID>
  </reference>
  <reference>
    <citation>Kikuchi-Utsumi K, Ishizaka M, Matsumura N, Nakaki T. Alpha(1A)-adrenergic control of piloerection and palpebral fissure width in rats. Auton Neurosci. 2013 Dec;179(1-2):148-50. doi: 10.1016/j.autneu.2013.04.011. Epub 2013 May 20.</citation>
    <PMID>23701912</PMID>
  </reference>
  <reference>
    <citation>Esmaeli-Gutstein B, Hewlett BR, Pashby RC, Oestreicher J, Harvey JT. Distribution of adrenergic receptor subtypes in the retractor muscles of the upper eyelid. Ophthalmic Plast Reconstr Surg. 1999 Mar;15(2):92-9.</citation>
    <PMID>10189635</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Oded Sagiv</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>eyelid retraction</keyword>
  <keyword>tamsulosin</keyword>
  <keyword>alpha receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Eyelid Diseases</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

